Search

Your search keyword '"Thomas W Weickert"' showing total 128 results

Search Constraints

Start Over You searched for: Author "Thomas W Weickert" Remove constraint Author: "Thomas W Weickert"
128 results on '"Thomas W Weickert"'

Search Results

1. Genetic Overlap Between Alzheimer’s Disease and Bipolar Disorder Implicates the MARK2 and VAC14 Genes

2. Perceptual category judgment deficits are related to prefrontal decision-making abnormalities in schizophrenia

3. Testosterone is inversely related to brain activity during emotional inhibition in schizophrenia.

5. Peripheral NF-κB dysregulation in people with schizophrenia drives inflammation: putative anti-inflammatory functions of NF-κB kinases

6. Raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A study protocol

7. Efficacy of Transcranial Direct Current Stimulation to Improve Insight in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials

8. Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium

9. Correction: Obesity and brain structure in schizophrenia – ENIGMA study in 3021 individuals

10. Obesity and brain structure in schizophrenia - ENIGMA study in 3021 individuals

11. Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions

12. The impact of smoking status on cognition and brain morphology in schizophrenia spectrum disorders

13. Altered levels of immune cell adhesion molecules are associated with memory impairment in schizophrenia and healthy controls

15. Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders

16. Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors

17. White Matter Disruptions in Schizophrenia Are Spatially Widespread and Topologically Converge on Brain Network Hubs

18. Peripheral complement is increased in schizophrenia and inversely related to cortical thickness

19. Transcriptional changes in the stress pathway are related to symptoms in schizophrenia and to mood in schizoaffective disorder

20. Evidence for Network-Based Cortical Thickness Reductions in Schizophrenia

21. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia

22. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology

23. Cortisol-dehydroepiandrosterone ratios are inversely associated with hippocampal and prefrontal brain volume in schizophrenia

24. Raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A study protocol

25. Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions

26. Genome-wide association study of over 40,000 bipolar disorder cases provides new insights into the underlying biology

27. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology

28. Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA

29. The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls

30. Neutrophil-lymphocyte ratio - a simple, accessible measure of inflammation, morbidity and prognosis in psychiatric disorders?

31. Exploring the moderating effects of dopaminergic polymorphisms and childhood adversity on brain morphology in schizophrenia-spectrum disorders

32. Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation

33. Probabilistic association learning in schizophrenia

34. Widespread Volumetric Reductions in Schizophrenia and Schizoaffective Patients Displaying Compromised Cognitive Abilities

35. Accelerated Gray and White Matter Deterioration With Age in Schizophrenia

36. M62. PERIPHERAL INFLAMMATION MARKERS IDENTIFY SUBSET OF PATIENTS WITH SCHIZOPHRENIA AND RELATED PSYCHOSES WHO HAVE INTELLECTUAL DECLINE FROM PREMORBID LEVELS

37. Raloxifene increases prefrontal activity during emotional inhibition in schizophrenia based on estrogen receptor genotype

38. The effects of a muscarinic receptor 1 gene variant on cortical thickness and surface area in schizophrenia

39. Reward and punishment learning in schizophrenia and bipolar disorder

40. The Impact of Childhood Adversity on Cognitive Development in Schizophrenia

41. S33. REDUCTION IN PERIPHERAL C-REACTIVE PROTEIN LEVELS WITH CANAKINUMAB ADMINISTRATION IS RELATED TO REDUCED POSITIVE SYMPTOM SEVERITY IN PATIENTS WITH SCHIZOPHRENIA AND INFLAMMATION

42. A quantitative review of the postmortem evidence for decreased cortical N-methyl-d-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity deficits?

43. Peripheral Inflammation Markers Identify a Subset of Patients With Schizophrenia and Related Psychoses who Display Intellectual Decline From Premorbid Levels

44. Reply to:New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?

45. C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls

46. P.095 Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions

47. Sex-Specific Associations of Androgen Receptor CAG Trinucleotide Repeat Length and of Raloxifene Treatment with Testosterone Levels and Perceived Stress in Schizophrenia

48. Increased plasma Brain-Derived Neurotrophic Factor (BDNF) levels in females with schizophrenia

49. Differential effect of disease-associated ST8SIA2 haplotype on cerebral white matter diffusion properties in schizophrenia and healthy controls

50. 107. Reduction in Peripheral C-Reactive Protein Levels With Canakinumab Administration is Related to Reduced Positive Symptom Severity in Patients With Schizophrenia and Inflammation

Catalog

Books, media, physical & digital resources